Nectar Lifescience's Q1 FY 2026-27 Quarterly Results

Result Summary

• Nectar Lifescience Ltd reported a 55.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a decline of 98.8%.
• Its expenses for the quarter were down by 56.6% QoQ and 92.6% YoY.
• The net profit decreased 77.3% QoQ and decreased 75.6% YoY.
• The earnings per share (EPS) of Nectar Lifescience Ltd declined at 0.79 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Nectar Lifescience Ltd is a company operating in the pharmaceutical industry. The company focuses on the development, manufacture, and distribution of pharmaceutical products. Its main products include active pharmaceutical ingredients (APIs), pharmaceutical formulations, and herbal products. The company has positioned itself to serve both domestic and international markets, leveraging its facilities for a range of healthcare solutions. As of the last update, there are no specific recent developments publicly available for Nectar Lifescience Ltd. The company remains committed to innovation in pharmaceuticals, maintaining a portfolio that addresses various therapeutic areas.

Revenue

In the first quarter of the fiscal year 2027 (Q1FY27), Nectar Lifescience Ltd recorded a total income of ₹3.36 crores. This represents a significant quarter-over-quarter (QoQ) decrease of 55.7% from ₹7.58 crores in the previous quarter (Q4FY26). On a year-over-year (YoY) basis, the total income plummeted by 98.8% from ₹281.02 crores in Q1FY26. These figures highlight substantial declines in revenue generation during this period, suggesting a challenging sales environment or other impacting factors in this quarter.

Profitability

The profitability metrics for Nectar Lifescience Ltd in Q1FY27 show a challenging financial period. The company reported a Profit Before Tax (PBT) of -₹24.62 crores, which is an improvement from -₹56.93 crores in Q4FY26, reflecting a 56.8% QoQ decrease in losses. Compared to Q1FY26, where PBT was -₹96.75 crores, there was a YoY reduction in losses by 74.6%. The Profit After Tax (PAT) for Q1FY27 was -₹15.40 crores, improving by 77.3% QoQ from -₹67.92 crores in Q4FY26, and by 75.6% YoY from -₹63.23 crores in Q1FY26. The Earnings Per Share (EPS) stood at -₹0.79, compared to -₹3.38 in Q4FY26, marking a 76.6% QoQ improvement, and further from -₹2.82 in Q1FY26, a 72.0% YoY improvement.

Operating Metrics

The total expenses for Nectar Lifescience Ltd in Q1FY27 were reported at ₹27.98 crores, showing a 56.6% decrease from ₹64.51 crores in Q4FY26, and a 92.6% reduction from ₹377.78 crores in Q1FY26. The tax expense for Q1FY27 was -₹8.90 crores, a decrease of 54.9% QoQ from -₹19.72 crores in Q4FY26 and a 73.4% decrease YoY from -₹33.52 crores in Q1FY26. These metrics indicate significant reductions in both costs and tax liabilities during the quarter.